Lisa C Casey1, William M Lee. 1. Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas 75390–8887, USA.
Abstract
PURPOSE OF REVIEW: We review here the recent literature regarding hepatitis C treatment through January 2012. We discuss newly approved therapies and their clinical trial data and discuss what can be expected in this rapidly changing field. RECENT FINDINGS: Two new directly acting antiviral agents were approved in 2011 for use in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to some patients with genotype 1 hepatitis C. Additional drugs using different viral targets are in development to further improve response rates, tolerance, and increase access to therapy. SUMMARY: Telaprevir and boceprevir were approved in 2011 for use against genotype 1 hepatitis C, in combination with pegylated interferon and ribavirin. In most populations of genotype 1 patients, response rates are much improved but increased treatment related anemia has been seen. Additional options for therapy, including interferon-free regimens, are still needed and are under development.
PURPOSE OF REVIEW: We review here the recent literature regarding hepatitis C treatment through January 2012. We discuss newly approved therapies and their clinical trial data and discuss what can be expected in this rapidly changing field. RECENT FINDINGS: Two new directly acting antiviral agents were approved in 2011 for use in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to some patients with genotype 1 hepatitis C. Additional drugs using different viral targets are in development to further improve response rates, tolerance, and increase access to therapy. SUMMARY:Telaprevir and boceprevir were approved in 2011 for use against genotype 1 hepatitis C, in combination with pegylated interferon and ribavirin. In most populations of genotype 1 patients, response rates are much improved but increased treatment related anemia has been seen. Additional options for therapy, including interferon-free regimens, are still needed and are under development.
Authors: Kathleen Rosa; Min Fu; Leen Gilles; Karin Cerri; Monika Peeters; Jeffrey Bubb; Jane Scott Journal: Health Qual Life Outcomes Date: 2014-06-11 Impact factor: 3.186
Authors: Jane Scott; Kathleen Rosa; Min Fu; Karin Cerri; Monika Peeters; Maria Beumont; Stefan Zeuzem; Donna M Evon; Leen Gilles Journal: BMC Infect Dis Date: 2014-08-26 Impact factor: 3.090
Authors: Stephen Youngberg; Erin Brandt; Avantika Barve; Surendra Machineni; Christopher T Jones; Kristina Dabovic; Catherine L Jones; Richard A Colvin Journal: J Drug Assess Date: 2018-10-24
Authors: C Mancone; F Ciccosanti; C Montaldo; A B Perdomo; M Piacentini; T Alonzi; G M Fimia; M Tripodi Journal: Clin Microbiol Infect Date: 2012-10-03 Impact factor: 8.067